DECEMBER 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
CHMP December 11. Aumolertinib – NSCLC EGFR. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorisation for the third-generation EGFR tyrosine kinase inhibitor for the treatment, as monotherapy, of: adult patients with advanced non small cell lung cancer […]